CLS: TO6B outcome - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

CLS: TO6B outcome - Redeye

{newsItem.title}

Redeye comments on the TO6B outcome. With underwriting commitments, the TO6B was subscribed at 100%, meaning that CLS will receive approximately SEK23.5m before issue-related costs. Based on the outcome and CLS’ business update in January, we will provide a more extensive research update in relation to the company’s Q4 2023 report. Until then, we set our estimates and fair value range “under review.”

Länk till analysen i sin helhet: https://www.redeye.se/research/975515/cls-to6b-outcome?utm_source=finwire&utm_medium=RSS

Nyheter om Clinical Laserthermia

Läses av andra just nu

Om aktien Clinical Laserthermia

Senaste nytt